| Webinar | Host | Action | |
|---|---|---|---|
| Webinars 1 & 2 Obesity / Rare & Chronic Disease |
 |
You will be redirected to the Fierce registration page, where you can select one or both sessions. Confirmation emails and reminders for these sessions will be sent by the Fierce events platform. | Register here |
| Webinars 3 & 4 Oncology / Women’s Health |
 |
Use the Clarivate form to pre-register for one or both of these sessions. You will receive confirmations and reminders directly from Clarivate. | Pre-register here |
Webinar theme
The global obesity drug market is accelerating toward a projected $150 billion by 2035, powered by groundbreaking GLP-1 innovation and next-generation metabolic therapies. In this first session of the Drugs to Watch 2026 webinar series, we will unveil the full 2026 report, highlighting 11 therapies expected to reshape treatment paradigms across metabolic disorders, rare diseases, oncology and women’s health.
Head of Global Thought Leadership, Clarivate
As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights support pharma, biotech, healthcare and medtech stakeholders in understanding market trends.
Lead Healthcare Research & Data Analyst, DRG Commercial Solutions
Shambhavi has authored competitive landscape and market insight reports covering metabolic disorders, with a focus on type 1 diabetes, type 2 diabetes, and GLP-1 RA products. She holds a master’s degree in biotechnology from Amity University.
Analyst, DRG Commercial Solutions, Clarivate
Carles has authored reports on cardiovascular and metabolic indications including obesity, acute coronary syndrome, and hyperkalemia. He previously conducted research at the Francis Crick Institute and IRB Barcelona and holds a Ph.D. in genetics.
Webinar theme
The chronic disease and inflammation landscape is undergoing profound transformation. Rather than managing symptoms, next-generation precision therapies are increasingly targeting the root immunological drivers of disease, enabling remission discussions and halting progression across multiple therapeutic areas.
This webinar explores four groundbreaking anti-inflammatory and disease-modifying therapies that exemplify this paradigm shift:
Through in-depth clinical and commercial analysis from leading industry specialists at Clarivate, we will examine the pivotal clinical trial evidence, competitive positioning, market impact, and the specific unmet needs each therapy addresses.
Discover how convenient delivery systems, precision mechanisms, and disease-modifying potential are reshaping treatment algorithms—and the commercial and regulatory hurdles each must overcome to achieve blockbuster status.
Register here
Head of Global Thought Leadership, Clarivate
As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights and analysis support pharma, biotech, healthcare and medtech stakeholders gain a deeper understanding of market news and trends.
Lead Healthcare Research & Data Analyst, VOYXACT (sibeprenlimab) for IgAN
Archita has authored reports on hematological indications, infectious diseases, and rare indications. She holds double master’s degrees in Business Administration and Science with specialization in Biotechnology.
Associate Healthcare Research & Data Analyst (Immune & Inflammation)
Icotrokinra for Plaque Psoriasis. Before joining Clarivate, she was a senior business analyst at AdametNext and holds a master’s in pharmacoinformatics from NIPER.
Senior Manager, Healthcare Research & Data Analytics, Tolebrutinib for Multiple Sclerosis
Mohit Nasa is a Senior Manager on the Immune and Inflammatory team at Clarivate. He holds a Bachelor’s degree in Pharmacy and has earned an MBA in Marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business Analyst at Novartis, where he was responsible for end-to-end Market assessment, reporting analytics, and related projects for Novartis’s asthma brand, Xolair. Mohit has also worked as Brand manager at Ozone Pharma and handled brand planning and related activities of a topical analgesic and anti-inflammatory brand called DFO Gel, and has also worked as Account manager for IMS Health. Mohit has diverse experience working on several immunology indications, including asthma, COPD, SLE, rheumatoid arthritis, and psoriasis.
Healthcare Research & Data Analyst, Depemokimab for Severe Asthma
In his role at Clarivate, Mr. Pareek brings several years of experience in market research. Prior to joining Clarivate, he worked in a market research and consulting firm, where he oversaw several projects in both the pharmaceutical and biotechnology domains. He holds a master's degree in biotechnology from Lovely Professional University in Punjab, India.